Source: global Tiger Finance app

Concept fire of synthetic biologyBestlaboucheresequenceChuanning Bio also ushered in a wave of stock price surge. It is worth mentioning that the company, which just went public at the end of 2022, relies on Karen Pharmaceutical Co., Ltd., in fact, the "infusion king" Liu Innovation. Not long ago, Colin Botai, another subsidiary of Colin Pharmaceutical, just rang the bell on the Hong Kong Stock Exchange. Liu now owns three listed companies with a combined market capitalization of more than $100 billion.

Riding on the east wind of synthetic organisms, Chuanning biology is finally "exuberant"BestlaboucheresequenceGot a hand.

On April 30th, the concept of synthetic biology rose sharply, and the related concept stocks all turned red. Chuanning Biology, Fujilai and Yidoli harvested the 20CM limit, while Lu Kang Medicine, Shengda Biology, Azure Biology and Boen Group harvested 10CM.

It is reported that through the idea of engineering, synthetic biology recompiles the functional codes of organisms, such as enzymes, synthetic pathways and metabolic regulatory networks of chassis cells, in order to design organisms with new functions and complete a new science for specific purposes. This emerging technology was mentioned not long ago at the Central Economic work Conference and the annual meeting of the 2024 Zhongguancun Forum.

It is worth mentioning that Chuanning Biology, which has received this wave of rising dividends, is the controlling subsidiary of Coren Pharmaceutical Co., Ltd., and is also the second listed company under "infusion king" Liu Xin. Prior to the arrival of Colombo on the Hong Kong Stock Exchange in July 2023, Liu already owns three listed companies and belongs to three major business sectors.

Synthetic organism belt Feichuanning organism

On April 30, Chuanning Biology quickly pulled up and harvested 20CM. The company rose more than 12% the day before. As of the close, Chuanning Biology News 13.Bestlaboucheresequence.18 yuan per share, with a current market capitalization of 293Bestlaboucheresequence0 billion yuan.

On the news side, at the annual meeting of the 2024 Zhongguancun Forum held on April 25-29, Academician Tan Tianwei said: bio-manufacturing is a very important new track and new business type for new productivity, which is currently led by the National Development and Reform Commission (NDRC). State ministries such as the Ministry of Industry and Information Technology and the Ministry of Science and Technology are jointly developing a national action plan for biotechnology and biological manufacturing, which is expected to be released in the near future.

Earlier, the Central Economic work Conference mentioned that synthetic biotechnology is "subversive" and that there has been a marked increase in local support policies for synthetic biology. It can be said that synthetic biology has become a new outlet in the field of biopharmaceuticals.

How did Chuanning biology get a ride on synthetic biology?

It is understood that synthetic biology is an interdisciplinary field based on engineering concepts, combined with multidisciplinary knowledge, which provides a unique perspective for the transformation and creation of artificial life systems.

According to Chuanning Biology, the company belongs to the pharmaceutical manufacturing industry, and is currently mainly engaged in the research, development and industrialization of biological fermentation technology and synthetic biological products.

The company's synthetic biology project covers an area of 591mu and is divided into two phases, with a total investment of 1 billion yuan. the first phase of the project has two flexible production lines of cosmetic raw materials and health products raw materials. the main products include red myrrh alcohol, 5-hydroxytryptophan, Iketoin, salidroside, ergothione and so on.

With "face", the performance of "Li Zi" of Chuanning biology is also good. After the company went public in December 2022, the ability to make money has also made a qualitative leap.

According to the annual report released on April 22nd, Chuanning Bio achieved a total revenue of 4.823 billion yuan in 2023, an increase of 26.24% over the same period last year, while its net profit was 941 million yuan, an increase of 128.56% over the same period last year.

The first quarterly report for 2024, disclosed on the same day, showed that revenue during the company period was 1.523 billion yuan, an increase of 19.96 percent over the same period last year, and the net profit of returning home was 353 million yuan, an increase of 100.98 percent over the same period last year.

It is worth mentioning that Chuanning Biology is the controlling subsidiary of Koren Pharmaceutical Co., Ltd., which relies on the "infusion king" Liu Xin. At present, Coren Pharmaceutical holds 1.57 billion shares of the company, accounting for 70.63% of the company's total share capital, and is the controlling shareholder of the company. Liu Xin holds 19.27% of the company and is the actual controller of the company.

Liu Xin, who holds three listed companies

The 73-year-old Liu still occupies a place in the pharmaceutical industry, which is full of bigwigs.

With Columbine, another subsidiary of Colin Pharmaceutical, officially landed on the Hong Kong Stock Exchange on July 11, 2023, Liu gained the third IPO in his life.

It is worth mentioning that Colombo at that time also set the record for the largest IPO of Hong Kong stocks that year with a total fund raised of HK $1.259 billion.

As a well-known entrepreneur compared with Liu Yonghao in Sichuan, Liu Innovation's entrepreneurial story is also quite legendary.

In 1975, Liu Xin, who graduated from university, was assigned to work in a state-run pharmaceutical factory and won the "iron rice bowl". Then, driven by the wind of reform in the Bashu region, Liu resigned from public office to join the Sino-US joint venture Sichuan Qili Pharmaceutical Co., Ltd.

Liu's entrepreneurial path began at the end of 1995, when he was 44 years old, just as investment in the pharmaceutical industry began to open to private capital. Soon, Liu Xin borrowed 1 million yuan and came to Chengdu with his entrepreneurial partners. after carrying out technical transformation of a capsule factory, he established Sichuan Kelun Pharmaceutical Co., Ltd., the predecessor of Koren Pharmaceutical Co., Ltd., with infusion products as the main business. Liu Xin served as the chairman of the company.

In 2003, Kelunda Pharmaceutical Co., Ltd. was changed into Sichuan Kelun Pharmaceutical Co., Ltd. The development of the company is also gradually on the right track. From 2003 to 2009, Liu spent 150 million yuan on mergers and acquisitions of 13 companies, and his assets are growing. In 2010, Coren Pharmaceutical was finally successfully listed on the Shenzhen Stock Exchange.

At present, Liu Sichuan, Liu's son, inherited his father's career and served as the general manager of Koren Pharmaceutical Co., Ltd., becoming a veritable "second generation of medicine."

Judging from the current shareholder composition of Coren Pharmaceutical, Liu Xin directly holds a total of 23.67% of Coren Pharmaceutical Co., Ltd.

But listing is not the end, Liu Innovation soon opened the road to the transformation of Coren Pharmaceutical Industry. He chose "three parts of the world" and set up Chuanning Biology and Karen Botai successively. At present, there is a clear division of labor among the three major business sectors of Coren. The parent company, Coren Pharmaceutical, is responsible for large infusion and generic drugs, and the business of antibiotic intermediates and APIs is spun off to Chuanning Biology, while Kroenbotai focuses on creating new drugs.

Now the three listed companies have a combined market capitalization of more than 100 billion yuan, and Liu Xin was listed on the Hurun Rich list in 2023 with a fortune of 11.5 billion yuan.

Spin-off subsidiaries listed on the market to repay debts

　　光鲜背后，科伦药业也有过一段“负重前行”的日子。

　　科伦药业曾表示，分拆两个子公司上市除了在业务上细分整合外，通过发行可转债、川宁上市融资、博泰融资，可严格控制固定资产投资等措施可降低负债，并争取未来两三年内将负债率降至40%以下。

　　而过去科伦药业也确实因为对两家子公司的出钱又出力而负债率高企。

　　2011年3月，刚上市不久的科伦药业就发布公告，拟建设“伊犁川宁生物技术有限公司抗生素中间体建设项目”，项目总投资39.92亿元，其中拟使用超募资金16.44亿元。科伦药业董秘在2020年年底透露，其融资40亿元至50亿元基本上都用于川宁生物。至今，科伦药业对川宁生物投入已近百亿。

　　除了提供资金外，科伦药业还常年为川宁生物提供担保，2019年至2021年科伦药业为川宁生物提供的担保金额分别为4亿元、33.9亿元和9.1亿元。2021年更是10次发布为川宁生物提供担保的公告。

　　对于科伦博泰科伦药业同样投入颇多，同时，公司还未实现盈利，2021-2023年其归母净利润分别亏损8.23亿元、5.48亿元以及5.22亿元。

　　在这样的情况下，2022年底，科伦药业的负债总额达173.35亿元，资产负债率高达50.50%。

　　不过，随着两家子公司成功上市融资，科伦药业可以说是守得云开见月明，川宁生物上市时就有4亿元被用来还债，截至2024年一季度，科伦药业的资产负债率已经降至31.33%。

　　同时，科伦药业的营收、净利润也重回双位数增长。2024年一季度公司实现营收62.19亿元，同比增长10.32%；归母净利润为10.26亿元，同比增长26%。

　　责任编辑 | 陈斌